In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells
Zhang Yueting
Guan Lingxia
Dong Pingshuan
Abstract：Objective To study the expression of IL-35 in the heart of Coxsackie virus B3 (CVB3) -induced viral myocarditis model. Methods BALB / c mice were infected with CVB3 to establish a model of viral myocarditis as an infection group (IF group). IL-35-treated mice were treated with IL-35 after infection. Mice infected with plasmid-free plasmids were infected with p-FC group, The expression of IL-35 was measured by enzyme-linked immunosorbent assay (ELISA), and Th17 ratio was measured by flow cytometry. Myocardities score was assessed after HE staining. Results The body weight of BALB / c mice decreased gradually (22.3±4.2) g, (18.3 ±2.6) g, (17.1±2.4) g and (13.2±1.8) g respectively after 1, 3, 5 and 7 days of CVB3 infection. Myocarditis score gradually increased 0.5 points, 1.5 points, 3.0 points and 4.0 points, respectively, and intraperitoneal injection of IL-35 expression plasmid can alleviate the mouse weight and myocarditis score increased. There was a negatively correlated between the expression of IL-35 and the body weight of BALB/c mice (r=-0.532, P=0.034), myocardities score (r=-0.670, P=0.005). At the 7th day of CVB3 infection, the ratio of Th17 cells in spleen of mice treated with IL-35 was significantly decreased (P<0.05). Conclusions IL-35 expression in cardiac tissue may be due to inhibition of splenic Th17 cells in the treatment of coxsackievirus B3-induced viral myocarditis.
Keywords：IL-15Th-17 cellsCoxsackievirus B3Viral myocarditis
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 218-220,223 )